Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011384 | 0.80 | MAPT (0.38) | HRH3POLBKDM4EALDH1A1 | |
| SCHEMBL1010938 | 0.80 | LTA4H (0.33) | FAAHMGLLAKR1C3 | |
| SCHEMBL1011864 | 0.80 | MAPT (0.47) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1012009 | 0.79 | MAPT (0.44) | POLBL3MBTL1KDM4EALDH1A1MEN1 | |
| SCHEMBL1012646 | 0.76 | L3MBTL1 (0.45) | HRH3MGLLPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL1012040 | 0.76 | KDM4E (0.40) | MGLLPOLBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1010053 | 0.76 | DRD4 (0.40) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL11525936 | 0.75 | L3MBTL1 (0.41) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL11530804 | 0.74 | MAPT (0.46) | POLBL3MBTL1KDM4EALDH1A1MEN1 | |
| SCHEMBL1011200 | 0.73 | MAPT (0.49) | POLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | claimed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | claimed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | claimed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | claimed |
| US-20120241250-A1 | Aerial Work Platforms and Aerial Work Platform Assemblies Comprised of Polymerized Cycloolefin Monomers | EAKIN GEORGE R (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | disclosed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | disclosed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | disclosed |
| US-4161528-A | INSECTICIDES; MITICIDES | CELAMERCK GMBH & CO. KG. (DE) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | HRH3 1569/4885FAAH 532/4885MGLL 1421/4885 |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | HRH3 1569/4885FAAH 532/4885MGLL 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.